133 related articles for article (PubMed ID: 2253407)
1. Serum soluble interleukin 2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapy.
Chow CC; Lai KN; Leung JC; Chan JC; Cockram CS
Clin Endocrinol (Oxf); 1990 Sep; 33(3):317-21. PubMed ID: 2253407
[TBL] [Abstract][Full Text] [Related]
2. [The association of Graves' disease with serum soluble interleukin 2 receptor].
Ren YZ; Song ZG
Zhonghua Yi Xue Za Zhi; 1993 May; 73(5):264-5, 317. PubMed ID: 8221241
[TBL] [Abstract][Full Text] [Related]
3. Single daily dose short term carbimazole therapy for hyperthyroid Graves' disease.
MacFarlane IA; Davies D; Longson D; Shalet SM; Beardwell CG
Clin Endocrinol (Oxf); 1983 Jun; 18(6):557-61. PubMed ID: 6411390
[TBL] [Abstract][Full Text] [Related]
4. T lymphocyte activation in euthyroid Graves' ophthalmopathy: soluble interleukin 2 receptor release, cellular interleukin 2 receptor expression and interleukin 2 production.
Lai KN; Leung JC; Chow CC; Cockram CS
Acta Endocrinol (Copenh); 1989 May; 120(5):602-9. PubMed ID: 2786308
[TBL] [Abstract][Full Text] [Related]
5. Dynamic changes in soluble interleukin-2 receptor levels during treatment of Graves' disease. Correlation with disease activity.
Weryha G; Gobert B; Leclère J; Béné MC; Faure G; Hartemann P
Horm Res; 1991; 35(1):8-12. PubMed ID: 1916654
[TBL] [Abstract][Full Text] [Related]
6. Circulating soluble interleukin 2 receptor concentration is increased in both immunogenic and nonimmunogenic hyperthyroidism.
Mariotti S; Caturegli P; Barbesino G; Del Prete GF; Chiovato L; Pinchera A
J Endocrinol Invest; 1991 Oct; 14(9):777-81. PubMed ID: 1761814
[TBL] [Abstract][Full Text] [Related]
7. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
McIver B; Rae P; Beckett G; Wilkinson E; Gold A; Toft A
N Engl J Med; 1996 Jan; 334(4):220-4. PubMed ID: 8531998
[TBL] [Abstract][Full Text] [Related]
8. [Serum thyroid hormones and TSH response to TRH during treatment of Graves' disease by carbimazole (author's transl)].
Lorcy Y; Heim J; Auvray E; Allannic H
Ann Endocrinol (Paris); 1979; 40(4):441-2. PubMed ID: 117739
[TBL] [Abstract][Full Text] [Related]
9. The effect of carbimazole therapy on interleukin 2, interleukin 2 receptors and free radicals.
Wilson R; McKillop JH; Buchanan LM; Bradley H; Smith WE; Thomson JA
Autoimmunity; 1990; 8(1):3-7. PubMed ID: 2129783
[TBL] [Abstract][Full Text] [Related]
10. High levels of serum soluble interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism.
Koukkou E; Panayiotidis P; Alevizou-Terzaki V; Thalassinos N
J Clin Endocrinol Metab; 1991 Oct; 73(4):771-6. PubMed ID: 1909702
[TBL] [Abstract][Full Text] [Related]
11. Serum cytokines in thyrotoxicosis.
Siddiqi A; Monson JP; Wood DF; Besser GM; Burrin JM
J Clin Endocrinol Metab; 1999 Feb; 84(2):435-9. PubMed ID: 10022397
[TBL] [Abstract][Full Text] [Related]
12. Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL-2) receptor (sIL-2R) in thyroid diseases.
Mariotti S; Caturegli P; Barbesino G; Marinò M; Del Prete GF; Chiovato L; Tonacchera M; De Carli M; Pinchera A
Clin Endocrinol (Oxf); 1992 Nov; 37(5):415-22. PubMed ID: 1486691
[TBL] [Abstract][Full Text] [Related]
13. Prediction of outcome in Graves' disease after carbimazole treatment.
Weetman AP; Ratanachaiyavong S; Middleton GW; Love W; John R; Owen GM; Darke C; Lazarus JH; Hall R; McGregor AM
Q J Med; 1986 Apr; 59(228):409-19. PubMed ID: 2875484
[TBL] [Abstract][Full Text] [Related]
14. Serum-soluble interleukin-2 receptor levels before and after surgical treatment for Graves' disease.
Murakami S; Kobayashi A; Kuma K; Murai H; Okamura Y; Satomi A; Ishida K
Surg Today; 1995; 25(1):55-8. PubMed ID: 7538365
[TBL] [Abstract][Full Text] [Related]
15. [Plasmatic thyroid hormones during treatment of hyperthyroidism by carbimazol (author's transl)].
Linquette M; Lefebvre J; Benoit G; Racadot A
Ann Endocrinol (Paris); 1977; 38(2):169-70. PubMed ID: 578398
[TBL] [Abstract][Full Text] [Related]
16. Increased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugs.
Tsatsoulis A; Vlachoyiannopoulos PG; Dalekos GN; Johnson EO; Moutsopoulos HM
Eur J Clin Invest; 1995 Sep; 25(9):654-8. PubMed ID: 7498238
[TBL] [Abstract][Full Text] [Related]
17. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
Chen JJ; Ladenson PW
J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
[TBL] [Abstract][Full Text] [Related]
18. Studies of thyroid hormone and methimazole levels in patients with Graves' disease on a standardized anti-thyroid drug regimen.
Dahlberg PA; Karlsson FA; Lindström B; Wide L
Clin Endocrinol (Oxf); 1981 Jun; 14(6):555-62. PubMed ID: 6895351
[TBL] [Abstract][Full Text] [Related]
19. Thyroid function tests during carbimazole therapy.
Scott DL; Tymms DJ; Taylor MA; Chapman C
Postgrad Med J; 1980 Dec; 56(662):838-41. PubMed ID: 6894979
[TBL] [Abstract][Full Text] [Related]
20. Evidence for carbimazole as an antioxidant?
Wilson R; Buchanan L; Fraser WD; Jenkins C; Smith WE; Reglinski J; Thomson JA; McKillop JH
Autoimmunity; 1998; 27(3):149-53. PubMed ID: 9609132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
